173 related articles for article (PubMed ID: 27912175)
1. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Pan J; Hao Q; Li Y; Zhou W
Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
[TBL] [Abstract][Full Text] [Related]
7. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
[TBL] [Abstract][Full Text] [Related]
9. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
12. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
Li X; Shi B; Teng Y; Cheng Y; Yang H; Li J; Wang L; He S; You Q; Xiang H
Medchemcomm; 2019 Feb; 10(2):294-299. PubMed ID: 30881616
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
19. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]